Performance Characteristics of a PCR Assay for the Detection of KRAS Mutations in Formalin-Fixed Paraffin-Embedded Tissue Samples of Non-Small Cell Lung Cancer

Lee, Sung; Cao, Jianli; May, Theresa; Li, Jingchuan; Corona, Lilia; Lee, Nitta; Wu, Yiching; Wong, Carrie R.; DeMartin, Kelli; Brophy, Victoria H.; Soviero, Stephen; Palma, John F.

doi:10.4172/2155-9929.1000246

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the case, even though several more sensitive commercial methods for KRAS mutation testing are now available. These include next-generation sequencing (NGS) methods with LODs of 1–10%, depending on platform and coverage [ 18 , 20 – 22 ], mass spectrometry-based methods with LODs down to 5% [ 23 ], and real-time PCR-based methods such as cobas ® KRAS mutation test (Roche, LOD of 2.4–12.1%) [ 24 ], therascreen ® KRAS RGQ PCR kit (Qiagen, LOD of 0.5–1%) [ 20 ], and Idylla™ KRAS Mutation Test (Biocartis, LOD ≥5–10%) [ 25 ]. Digital droplet PCR (ddPCR) is the latest addition to the technologies available for KRAS mutation testing recently demonstrating a LOD as low as 0.0005%, although a large amount of DNA was required to achieve these levels [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

SensiScreen® KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations

Riva¹,

Børgesen²,

Guldmann-Christensen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Activating mutations in codon 12 and codon 13 of the KRAS (Kirsten rat sarcoma viral oncogene homolog) gene are implicated in the development of several human cancer types and influence their clinical evaluation, treatment and prognosis. Numerous different methods for KRAS genotyping are currently available displaying a wide range of sensitivities, time to answer and requirements for laboratory equipment and user skills. Here we present SensiScreen® KRAS exon 2 simplex and multiplex CE IVD assays, that use a novel real-time PCR-based method for KRAS mutation detection based on PentaBase’s proprietary DNA analogue technology and designed to work on standard real-time PCR instruments. By means of the included BaseBlocker™ technology, we show that SensiScreen® specifically amplifies the mutated alleles of interest with no or highly subdued amplification of the wild type allele. Furthermore, serial dilutions of mutant DNA in a wild type background demonstrate that all SensiScreen® assays display a limit of detection that falls within the range of 0.25–1%. Finally, in three different colorectal cancer patient populations, SensiScreen® assays confirmed the KRAS genotype previously determined by commonly used methods for KRAS mutation testing, and notably, in two of the populations, SensiScreen® identified additional mutant positive cases not detected by common methods.

show abstract

Section: Introductionmentioning

confidence: 99%

SensiScreen® KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations

Riva¹,

Børgesen²,

Guldmann-Christensen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

Lung Cancer: Brief Account of Advanced and Traditional Treatments and Diagnosis

Shaikh¹,

Bangal²,

Rituja³

et al. 2016

Arch Can Res

View full text Add to dashboard Cite

Lung cancer is an uncontrolled growth of lung cells that's lead to form a tumour. More than 20% of total cancer death is due to lung cancer. There are mainly two types of effective treatments available viz. traditional and advance. Each treatment has their pros and cons, but the advance and latest treatment has upper hand as well as effective results compared to the traditional one. Both Traditional chemotherapy and radiotherapy have restricted impact on advance stage of cancer. This review provides comparative account of traditional and advances in lung cancer treatment.

show abstract

Performance Characteristics of a PCR Assay for the Detection of KRAS Mutations in Formalin-Fixed Paraffin-Embedded Tissue Samples of Non-Small Cell Lung Cancer

Cited by 2 publications

References 13 publications

SensiScreen® KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations

SensiScreen® KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations

Lung Cancer: Brief Account of Advanced and Traditional Treatments and Diagnosis

Contact Info

Product

Resources

About